News

QuantRx has formed a joint venture with NuRx, to accelerate efforts to capitalize opportunities in the fast growing market for Point-of-Care (POC) products. In addition to benefiting from

Merge Healthcare has signed a new contract with the Center for Diagnostic Imaging (CDI) based in Minneapolis, MN. The solution will debut at the CDI center in Sartell,

ImmunoGen has provided the initial efficacy, safety and tolerability clinical data of IMGN901, for the treatment of small-cell lung cancer (SCLC). IMGN901 is in early clinical testing and

FDA has informed Genzyme that it will re-inspect the company’s Allston Landing manufacturing facility. The re-inspection is a follow-up to an inspection the agency conducted in May 2009,

Graceway has provided the results from a phase III program evaluating short-course regimens of two concentrations of imiquimod cream (3.75% and 2.5%). The data demonstrated imiquimod 3.75%, administered

FDA has announced a consent decree of permanent injunction filed, that prohibits Teva Animal Health, from manufacturing and distributing adulterated veterinary drugs. Under the terms of the consent

FDA has approved Invega Sustenna (paliperidone palmitate) extended-release injectable suspension for maintenance and treatment of schizophrenia in adults. The approval is based on four acute symptom control studies

Medarex has posted net loss for the quarter ended June 30, 2009 at $29.2 million, or $0.23 per share, as compared to a net loss of $53.1 million,

FDA has approved antipsychotic for the acute treatment of schizoaffective disorder. Invega (paliperidone) extended-release tablets were approved for the acute treatment of schizoaffective disorder, either as monotherapy or